AA536717 Inhibitors
Chemical inhibitors of AA536717 can act through various signaling pathways to inhibit its function. Wortmannin and LY294002 are both inhibitors of the phosphoinositide 3-kinase (PI3K) pathway. By inhibiting PI3K, these chemicals can prevent the activation of Akt, a kinase that plays a pivotal role in cell survival and proliferation. This blockade can lead to the inhibition of AA536717, assuming that its activity is regulated by or dependent on the PI3K/Akt pathway. Rapamycin, on the other hand, targets the mTOR pathway, another critical regulator of cell growth and metabolism. By inhibiting mTOR, Rapamycin can suppress the downstream effects of mTOR activation, which may include the regulation of AA536717. This suppression can result in the inhibition of AA536717's function, provided that mTOR signaling plays a role in its regulation.
Other inhibitors, such as PD98059 and U0126, can inhibit AA536717 by targeting the MAPK/ERK pathway. These chemicals inhibit MEK, which is upstream of ERK in the signaling cascade. By preventing the activation of ERK, PD98059 and U0126 can inhibit AA536717 if it is regulated by the MAPK/ERK pathway. Similarly, SB203580 inhibits the p38 MAPK pathway, which is involved in responses to stress and inflammation. By blocking p38 MAPK, SB203580 can inhibit AA536717 if it is associated with this pathway. SP600125, which inhibits JNK, and PP2, which targets Src family kinases, can also inhibit AA536717 by disrupting their respective signaling pathways. Dasatinib, with its broad-spectrum kinase inhibition, can inhibit multiple pathways, potentially affecting the function of AA536717. Proteasome inhibitors such as Bortezomib and MG132 can lead to the accumulation of proteins that regulate AA536717, thereby inhibiting its function. Finally, Staurosporine, a potent protein kinase inhibitor, can inhibit AA536717 directly if it exhibits kinase activity or indirectly if it is regulated by specific kinases that Staurosporine can inhibit.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. It can inhibit AA536717 by blocking the PI3K/Akt pathway, which is crucial for cell survival and proliferation, potentially leading to the functional inhibition of AA536717 if this protein is regulated by or dependent on this pathway for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can inhibit AA536717 by interfering with the mTOR signaling pathway. mTOR is a key regulator of cell growth, proliferation, and survival. Inhibition of mTOR can decrease the activity of downstream proteins that are essential for these processes, thereby inhibiting the function of AA536717. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, which can inhibit AA536717 by blocking the PI3K/Akt signaling pathway. This blockade can prevent the activation of downstream targets that are critical for the functional activity of AA536717, resulting in its inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can inhibit AA536717 by preventing the activation of the MAPK/ERK pathway. By inhibiting MEK, PD98059 indirectly prevents the phosphorylation and activation of ERK, which may be necessary for the functional activity of AA536717. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor, which can inhibit AA536717 by blocking the MAPK/ERK signaling cascade. This interruption can result in the reduction of ERK-mediated signaling, which could be essential for the functional regulation of AA536717. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can inhibit AA536717 by blocking the p38 MAPK signaling pathway. This pathway is involved in stress responses and inflammation. Inhibition of p38 MAPK can lead to a decrease in the functional activation of proteins that are regulated by this pathway, potentially including AA536717. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 can disrupt the JNK signaling pathway, potentially leading to the functional inhibition of AA536717 if JNK activity is required for its regulation or activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. Src kinases are involved in various signaling pathways that regulate cell growth and differentiation. By inhibiting these kinases, PP2 can inhibit signaling pathways that may be required for the functional activity of AA536717. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases and Bcr-Abl. Its inhibition of these kinases can lead to the downregulation of signaling pathways that are potentially involved in the functional activation of AA536717. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of regulatory proteins, which may include inhibitors of AA536717. By stabilizing these inhibitors, Bortezomib can indirectly lead to the functional inhibition of AA536717 through the regulation of protein degradation pathways. | ||||||